Spectral AI, Inc. Class A MDAI

DALLAS, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the completion of the first Site Initiation Visit (“SIV”) associated with the commencement of a clinical study designed to support a label expansion of the Company’s FDA-cleared DeepView System™ for Burn Indication to include burns involvin

DALLAS, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced a scheduled presentation at the upcoming ACS Clinical Congress 2026, being held September 26-29, 2026 in Washington, DC. Entitled “Artificial Intelligence Training & Validation of Multi-Spectral Imaging Device for Evaluation of Burn Wounds

Announces Upcoming Burn Conference ScheduleDALLAS, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the Southern Regional Burn Conference (SRBC), held September 10-12, 2026 in Williamsburg, Virginia. The Company’s DeepView® System for Burn Indication was on dis

Company to Highlight Growth Strategy and Readiness for 2026 Commercial Launch of FDA-Cleared DeepView® System for Burn IndicationDALLAS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that Vincent Capone, Chief Executive Officer, and David McGuire, Chief Financial Officer, are scheduled to present

By John Vandermosten, CFA NASDAQ: MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ: MDAI) reported second quarter 2026 results on August 11 th after the market close. Since the previous financial update in May, the company has received De Novo marketing authorization for the DeepView system in the burn indication and has accelerated its pre-commercialization efforts. It further

Moby summary of Spectral AI, Inc.'s Q2 2026 earnings call

Company Continues to Advance Towards First Commercial Sales of the DeepView® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2026 (“Q2 2026”). “Spectral AI

DALLAS, July 29, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results for the second quarter ended June 30, 2026 on Tuesday, August 11, 2026, after the close of the Nasdaq stock market. The Company will host a corresponding conference call at 5:00 pm Eastern Time on the s

Industry Veteran Brings Two Decades of Experience Driving Growth Through New Product Launches, Training and EducationDALLAS, July 08, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced the appointment of Darcy Bajko as Chief Commercial Officer, effective July 31, 2026. Ms. Bajko will lead the commercial fun

Dr. Jeffrey Carter Awarded BBA Oral Presentation 1st Prize for his Paper on the Use of Multi-Spectral Imaging with Artificial Intelligence for Burn WoundsDALLAS, June 25, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today reflected on its successful participation at the British Burn Association (BBA) Annual Conferenc

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, is joining the American Board of Wound Management (ABWM) Foundation in celebrating the 10th Annual Wound Healing Awareness Month. In this milestone year, during the month of June the ABWM Foundation will continue its mission of raising awareness, empowerin

Company Will Showcase FDA-Cleared DeepView® System for Burn IndicationDALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced its participation in the upcoming British Burn Association (“BBA”) Annual Meeting, being held June 17-19, 2026 at the Nottingham Trent University, Nottingham, England. Th

Provides Update and Outlook Following Receipt of FDA De Novo Clearance for DeepView® System for Burn IndicationDALLAS, June 01, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2026 Annual Meeting of Stockholders, held on May 29, 2026. The Company also provided an overview of its accompli

By John Vandermosten, CFA NASDAQ: MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ: MDAI) announced De Novo clearance for its DeepView Burn diagnostic in a May 26 th  press release . As a result, we increase our probability of success for DeepView burn from 75% to 100%, which raises our valuation to $6.25 per share. Management’s attention will shift from regulatory matters

DALLAS, May 26, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the U.S. Food and Drug Administration (FDA) granted De Novo Classification for its DeepView® System. With this classification, Spectral AI is authorized to commence commercial distribution activities in the United States. The DeepView S

By John Vandermosten, CFA NASDAQ: MDAI READ THE FULL MDAI RESEARCH REPORT Spectral AI, Inc. (NASDAQ: MDAI) reported first quarter 2026 results on May 12 th after the market close. Since the previous financial update about a month and a half ago, the company has appointed David McGuire as Chief Financial Officer (CFO), presented DeepView at the American Burn Association, and received the Small

Spectral AI Inc (MDAI) outlines promising FDA submissions and strategic funding, despite facing revenue and cash flow hurdles.